CYP2D6 polymorphism in Parkinson's disease: The rottherdam study

Movement Disorders

Volumn 16, Issue 2, 2001, Pages 290-293

  Harhangi, B Sanjay ^a   Oostra, Ben A ^a   Heutink, Peter ^a   van Duijn, Cornelia M ^a   Hofman, Albert ^a   Breteler, Monique M B ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

CYP2D6; Epidemiology; Genetics; Parkinson's disease

Indexed keywords

CYTOCHROME P450 2D6;

ADULT; AGED; ALLELE; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FREQUENCY ANALYSIS; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALE; METABOLIC DISORDER; PARKINSON DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; SAMPLING; STATISTICAL SIGNIFICANCE; UNITED KINGDOM; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; FEMALE; GENE EXPRESSION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PARKINSON DISEASE; POLYMORPHISM, GENETIC; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES;

EID: 0035297113     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.1041     Document Type: Article

References (14)

1. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of Neurosurg Psychiatry 1992;55:181-184.
2. Barbeau A, Cloutier T, Roy M, Plasse L, Paris S, Poirier J. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet 1985;2:1213-1216.
3. Smith CA, Gough AC, Leigh PN, Summers BA, Harding AE, Maraganore DM, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992;339: 1375-1377.
4. Rostami-Hodjegan A, Lennard MS, Woods HF, Tucker GT. Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. Pharmacogenetics 1998;8: 227-238.
5. Hotamisligil GS, Girmen AS, Fink JS, Tivol E, Shalish C, Trofatter J, et al. Hereditary variations in monoamine oxidase as a risk factor for Parkinson's disease. Mov Disord 1994;9:305-310.
6. Hofmann A, Grobbee DE, de Jong PTVM, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991;7:403-422.
7. de Rijk MC, Breteler MMB, Graveland GA, Ott A, Grobbee DE, van der Meche FGA, et al. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology 1995;45:2143-2146.
8. Riedl AG, Watts PM, Jenner P, Marsden CD. P450 enzymes and Parkinson's disease: the story so far. Mov Disord 1998;13:212-220.
9. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336:529-532.
10. Cholerton S, Arpanahi A, McCracken N, Boustead C, Taber H, Johnstone E, et al. Poor metabolisers of nicotine and CYP2D6 polymorphism. Lancet 1994;343:62-63.
11. Gilham DE, Cairns W, Paine MJ, Modi S, Poulsom R, Roberts GC, et al. Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica 1997;27:111-125.
12. Bhatt MH, Elias MA, Mankodi AK. Acute and reversible parkinsonism due to organophosphate pesticide intoxication: five cases. Neurology 1999;52:1467-1471.
13. Suzuki T, Fujita S, Narimatsu S, Masubuchi Y, Tachibana M, Ohta S, et al. Cytochrome P450 isozymes catalyzing 4-hydroxylation of parkinsonism-related compound 1,2,3,4-tetrahydroisoquinoline in rat liver microsomes. Faseb J 1992;6:771-776.
14. Wilhelmsen K, Mirel D, Marder K, Bernstein M, Naini A, Leal SM, et al. Is there a genetic susceptibility locus for Parkinson's disease on chromosome 22q13? Ann Neurol 1997;41:813-817.